// Jian Qu 1, * , Ya-Nan Wang 2, * , Ping Xu 1 , Da-Xiong Xiang 1 , Rui Yang 3 , Wei Wei 4 , Qiang Qu 3 1 Department of Pharmacy, the Second Xiangya Hospital, Central South University, Institute of Clinical Pharmacy, Central South University, Changsha 410078, P.R.China 2 Department of Respiratory, Hospital of Laiwu Iron and Steel Co.Ltd, Laiwu 271100, P.R.China 3 Department of Pharmacy, Xiangya Hospital, Central South University, Changsha 410078, P.R.China 4 Department of General Surgery, Xiangya Hospital, Central South University, Changsha 410008, P.R.China * These authors contributed equally to this work Correspondence to: Jian Qu, email: qujianstanley@163.com Qiang Qu, email: quqiang2015@hotmail.com Keywords: icotinib, epidermal growth factor receptor, meta-analysis, objective response rate, disease control rate Received: November 11, 2016      Accepted: February 07, 2017      Published: February 18, 2017 ABSTRACT Icotinib is a novel and the third listed epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs), which exerts a good anti-tumor efficacy on non-small cell lung cancer (NSCLC). The efficacy of EGFR-TKIs has been shown to be associated with the EGFR mutation status, especially exon 19 deletion (19Del) and exon 21 L858R mutation. Therefore, a meta-analysis was performed to assess the efficacy of icotinib in NSCLC patients harboring EGFR mutations (19Del or L858R) and wild type (19Del and L858R loci wild type). A total of 24 studies were included for comparing the objective response rate (ORR) in the EGFR wild type and mutant patients treated with icotinib. The ORRs of EGFR mutant patients (19Del or L858R) are better than those of EGFR wild type patients (OR = 7.03(5.09–9.71), P < 0.00001). The pooling ORs from 21 studies on the disease control rate (DCR) in EGFR mutant patients are better than those of EGFR wild type patients (OR = 10.54(5.72–19.43), P < 0.00001). Moreover, the ORRs of EGFR 19Del patients are better than those of EGFR L858R patients after pooling ORs of 12 studies (OR = 2.04(1.12–3.73), P = 0.019). However, there was no significant difference on DCRs of EGFR 19Del patients and those of EGFR L858R patients (OR = 2.01(0.94–4.32), P = 0.072). Our findings indicated that compared with EGFR wild type patients, EGFR mutant patients have better ORRs and DCRs after icotinib treatment; EGFR 19Del patients treated with icotinib have better ORRs than EGFR L858R patients. EGFR mutation status is a useful biomarker for the evaluation of icotinib efficacy in NSCLC patients.

/pdf/clinical-efficacy-of-icotinib-in-lung-cancer-patients-with-1xv6s6shxb.pdf

Clinical efficacy of icotinib in lung cancer patients with different EGFR mutation status: a meta-analysis.

Objective To evaluate the efficacy and toxicity of icotinib,and to analyze prognostic factors influencing curative effect in patients with advanced non-small cell lung adenocarcinoma. Methods The clinical data of 90 non-small cell lung adenocarcinoma patients referred to the Jiangsu Cancer Hospital were retrospectively analyzed. Results All patients were evaluable for efficacy. Among the 90 patients,there was none with complete response( CR),55 patients with partial response( PR,61. 1%),28 patients with stable disease( SD,31. 1%) and 7 patients with progression disease( PD,7. 8%). The objective response rate( ORR) was 61. 1%,and the disease control rate( DCR) was 92. 2%. The total progressive free survival was 10. 5( 1. 3 ~ 22. 3) months. Among the 40 patients with EGFR mutations,there was none with CR,28 patients with partial response( PR,70. 0%),12 patients with stable disease( SD,30. 0%). The objective response rate( ORR) was 70. 0%,and the disease control rate( DCR) was 100%. Conclusions Icotinib is effective and safe in patients with advanced non-small cell lung adenocarcinoma.

Efficacy and safety of icotinib in patients with advanced non-small cell lung adenocarcinoma

Handle everyday research tasks with reliable, citation-backed results

Your personal Research Agent to handle research tasks with citation-backed results

Popular Tasks used by Researchers

How can I help with your research?

Meet SciSpace

Get more enhanced response by uploading the PDFs you want me to reference.

No relevant PDFs in your library

SciSpace is the AI research assistant for academics. Run systematic literature reviews on 280M+ papers, and write papers with cited sources. Trusted by 1M+ students, PhDs & researchers.

SciSpace | AI for Research

Analyze PDFs

Code & Manuscripts

Funding & Grants

Literature & Patents

Medical & Clinical Data

Systematic Review

Visualize & Present

Web & Data

Build a Google Scholar-like website for your research.

Build a website

Create charts and images for your research

Create a Chart

Write a paper for submission to a journal

Draft a manuscript

Patent Search

Design eye-catching scientific posters in minutes.

Scientific Poster Generation

Systematic Literature Review

One task is running at the moment. Your messages will be shown right after.

Drag and drop or click here to browse

Loved by <highlight>1 million+</highlight> researchers

Extract a list of specific topics and their sources from unstructured text

Topics

Compare and analyze relevant papers that matches with your search

Papers

Get insights from PDFs and bookmarked papers from your library

My library

Recent searches

Try searching for:

Catch AI-generated content in scholarly and non-scholarly content

{ai} Detector

Ai Writer

Get PDF Summaries, highlighted text explanations 

Chat with PDF

Effortlessly create in-text citations and bibliographies in APA and 2,500 other formats

Citation generator

Get explanations, summaries, and answers on academic papers

Ease up your research workflow with {scispace}'s cohort of exciting AI tools

Elevate your academic writing skills and convey your ideas the way you want

Paraphraser

Explore our range of reading and writing tools

Your file is being prepared and should be ready in a few minutes. If it's a large file, it might take a bit longer. You can close this window, and we'll email you the file when it's done.

You have reached a maximum limit of <strong>{limit}</strong> columns in the table. Remove at least <strong>1</strong> column to add or create another one.

MA Xiang-le

Author Tools

Chat about Author

Papers

Efficacy and safety of icotinib in patients with advanced non-small cell lung adenocarcinoma